Skip to main content
ASPI
NASDAQ Industrial Applications And Services

Renergen Subsidiary Locks in 5-Year Take-or-Pay LNG Deal, Bringing Phase 1 to 75% Contracted

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Chemical Stocks · Materials
Sentiment info
Positive
Importance info
7
Price
$4.1
Mkt Cap
$509.909M
52W Low
$3.51
52W High
$14.49
52W Position info
17% above low
Off High info
72% below high
Rel. Volume info
0.9× avg
Market data snapshot near publication time

ASPI sits 17% above its 52-week low of $3.51.

Summary

Renergen signed a five-year take-or-pay LNG contract with a South African food processor, covering ~10% of Phase 1 capacity and bringing total LNG offtake to 75%. Phase 1 remains on track for Q3 2026 startup.


Key Events · M&A and Partnerships · ASPI

  • New Take-or-Pay LNG Contract Signed

    Tetra4, a Renergen subsidiary, entered a five-year take-or-pay LNG sale and purchase agreement with a South African food processor at >$16/GJ, representing ~10% of Phase 1 nameplate capacity.

  • Phase 1 LNG Volumes 75% Contracted

    With this contract, Renergen has now secured take-or-pay contracts for approximately 75% of the LNG volumes anticipated from Phase 1, significantly de-risking the project's revenue base.

  • Phase 1 Commercial Production on Track for Q3 2026

    Phase 1 is expected to produce ~2,500 GJ/day of LNG and ~70 Mcf/day of liquid helium, with commercial production commencing in Q3 2026 and annualized revenue potential exceeding $27 million.

  • Revenue Recognition Expected in 2H 2026

    ASP Isotopes expects to begin recognizing revenues from Phase 1 during the second half of 2026, providing a near-term catalyst for the company's financials.


Analysis · ASPI · Industrial Applications And Services

ASP Isotopes' Renergen subsidiary has secured another multi-year take-or-pay LNG contract, lifting Phase 1 LNG volumes to 75% contracted. This milestone de-risks the project's revenue stream ahead of the targeted Q3 2026 commercial production and bolsters the >$27 million annualized revenue projection. Priced above $16/GJ, the contract adds cash-flow visibility just as the company navigates a complex reverse merger with ENDRA Life Sciences and a $50 million private placement.

At the time of this filing, ASPI was trading at $4.10 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $509.9M. The 52-week trading range was $3.51 to $14.49. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ASPI - Latest Insights

ASPI
Aug 06, 2026, 8:15 AM EDT
Filing Type: 425
Importance Score:
8
Price at Filing: $4.10
Real-time Price: $4.05 info
Change: -$0.050 (-1%) info
Market Cap: $509.909M info
ASPI
Aug 04, 2026, 5:25 PM EDT
Filing Type: 425
Importance Score:
9
Price at Filing: $4.32
Real-time Price: $4.05 info
Change: -$0.270 (-6%) info
Market Cap: $509.909M info
ASPI
Aug 04, 2026, 8:06 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $4.26
Real-time Price: $4.05 info
Change: -$0.2122 (-5%) info
Market Cap: $509.909M info
ASPI
Jul 22, 2026, 8:35 AM EDT
Filing Type: 425
Importance Score:
9
Price at Filing: $4.24
Real-time Price: $4.05 info
Change: -$0.190 (-4%) info
Market Cap: $509.909M info
ASPI
Jul 16, 2026, 5:00 PM EDT
Filing Type: S-3ASR
Importance Score:
8
Price at Filing: $4.08
Real-time Price: $4.05 info
Change: -$0.030 (-0.74%) info
Market Cap: $509.909M info